Sodium/glucose cotransporter: Difference between revisions
Michal Harel (talk | contribs) No edit summary |
Michal Harel (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
<StructureSection load='1stp' size='340' side='right' caption='Caption for this structure' scene=''> | <StructureSection load='1stp' size='340' side='right' caption='Caption for this structure' scene=''> | ||
This is a default text for your page '''Sodium/glucose cotransporter'''. Click above on '''edit this page''' to modify. Be careful with the < and > signs. | This is a default text for your page '''Sodium/glucose cotransporter'''. Click above on '''edit this page''' to modify. Be careful with the < and > signs. | ||
== Function == | == Function == | ||
Revision as of 10:34, 15 April 2024
This is a default text for your page Sodium/glucose cotransporter. Click above on edit this page to modify. Be careful with the < and > signs.
FunctionSodium/glucose cotransporter (SGLT) is responsible for glucose absorption across membranes. SGLT1 and SGLT2 which are expressed in different tissues, have similar active sites but differ in their non-active site structures. SGLT1 is responsible of glucose absorption in the small intestine and SGLT2 in kidney[1].SGLT2 is responsible of renal glucose absorption [2]. DiseaseRelevanceSGLT2 inhibitors aid in hypertension, acute cardiac failure, bradycardia, acute pulmonary oedema, asthma, bronchitis and COPD[3].. Structural highlightsThis is a sample scene created with SAT to by Group, and another to make of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes.
|
| ||||||||||
ReferencesReferences
- ↑ Poulsen SB, Fenton RA, Rieg T. Sodium-glucose cotransport. Curr Opin Nephrol Hypertens. 2015 Sep;24(5):463-9. PMID:26125647 doi:10.1097/MNH.0000000000000152
- ↑ Perry RJ, Shulman GI. Sodium-glucose cotransporter-2 inhibitors: Understanding the mechanisms for therapeutic promise and persisting risks. J Biol Chem. 2020 Oct 16;295(42):14379-14390. PMID:32796035 doi:10.1074/jbc.REV120.008387
- ↑ Jasleen B, Vishal GK, Sameera M, Fahad M, Brendan O, Deion S, Pemminati S. Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Benefits Versus Risk. Cureus. 2023 Jan 18;15(1):e33939. PMID:36819350 doi:10.7759/cureus.33939